Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
Civil society urges Member States to support the Dutch EU Presidency’s vision on access to affordable medicines
AMSTERDAM, 18 April 2016 —We strongly support the Dutch European Union (EU) Presidency’s critique of the current over-protection and misuse of intellectual property and related rights for pharmaceuticals, and its goal to better balance the reward for innovation against the assurance of affordability of medicines.
WHO Neglected Tropical Diseases Advisory Committee meetingWednesday 13 April 2016MSF intervention – Julien Potet, Access Campaign Dear NTD experts,
Last updated 13 April 2016
April 12th, 2016 Dear Member of Congress:
Last updated 12 April 2016
Geneva, 7 April 2016 Médecins Sans Frontières (MSF) wants to express its frustration that, in an already dramatic context of protracted violence and displacement, the warning we formulated a year ago to the humanitarian community and donors did not lead to any structural or decisive action to prevent a countrywide shortage of essential drugs.
Last updated 7 April 2016
MSF Written Submission to the Australian Parliament Joint Standing Committee on Treaties for consideration in the National Interest Analysis of the Trans-Pacific Partnership Agreement
Summary: Doctors Without Borders/Médecins Sans Frontières (MSF) provides the following written submission regarding the negative impact that the Trans-Pacific Partnership Agreement (TPP) will have on access to affordable medicines and biomedical innovation. MSF is an international independent humanitarian organization that provides medical assistance in over 60 countries, in need of both affordable access to and innovation for medical technologies.
Submission for US International Trade Commission Investigation No. TPA-105-001: “Trans-Pacific Partnership Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors”
February 16, 2016 Doctors Without Borders/ Médecins Sans Frontières (MSF) has provided oral testimony and a written submission regarding the negative impact that the Trans-Pacific Partnership (TPP) will have on access to affordable medicines and biomedical innovation. MSF is an international independent humanitarian organization that provides medical assistance in over 60 countries, in need of both affordable access to and innovation for medical technologies.
The United Nations Secretary-General Ban Ki-moon has convened a High-Level Panel on Access to Medicines “to review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies".
Last updated 29 March 2016
MSF appreciates Otsuka Pharmaceuticals’ donation of 400 treatments of a novel drug, delamanid, which enables MSF and its partners to initially treat a specific number of MDR-TB patients worldwide.
Last updated 19 February 2016
TO: Mr. Narendra Modi Honourable Prime Minister of IndiaGovernment of India Smt. Nirmala Sitharaman Honourable Minister of State for Commerce & Industry (Independent Charge) 3rd February 2016
Last updated 5 February 2016
Last updated 4 February 2016